Bryce Point Capital LLC Acquires Shares of 2,898 Charles River Laboratories International, Inc. (NYSE:CRL)

Bryce Point Capital LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,898 shares of the medical research company's stock, valued at approximately $535,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of CRL. Cerity Partners LLC boosted its position in Charles River Laboratories International by 65.9% in the 3rd quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company's stock valued at $963,000 after buying an additional 1,943 shares during the period. Glenmede Trust Co. NA increased its holdings in Charles River Laboratories International by 9.5% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,210 shares of the medical research company's stock worth $238,000 after purchasing an additional 105 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Charles River Laboratories International by 4.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,812 shares of the medical research company's stock valued at $1,933,000 after purchasing an additional 423 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Charles River Laboratories International by 15.1% in the 3rd quarter. Public Sector Pension Investment Board now owns 2,282 shares of the medical research company's stock worth $449,000 after buying an additional 300 shares during the period. Finally, Benjamin Edwards Inc. grew its position in shares of Charles River Laboratories International by 256.5% during the 3rd quarter. Benjamin Edwards Inc. now owns 1,451 shares of the medical research company's stock worth $286,000 after buying an additional 1,044 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their price objective for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Barclays reduced their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 18th. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average price target of $183.62.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded up $15.30 during midday trading on Wednesday, hitting $138.91. The company had a trading volume of 1,974,887 shares, compared to its average volume of 787,432. The stock has a market cap of $6.82 billion, a price-to-earnings ratio of 926.07, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12-month low of $117.26 and a 12-month high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $159.23 and a 200 day simple moving average of $178.36.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same quarter last year, the company posted $2.46 earnings per share. The business's quarterly revenue was down 1.1% on a year-over-year basis. As a group, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).